NCT02889666 A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
| NCT ID | NCT02889666 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Condition | Recurrent Non-small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2008-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 500 participants in total. It began in 2008-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if the commonly administered chemotherapeutic agents including cisplatin, carboplatin, oxaliplatin, docetaxel and gemcitabine for solid tumors in clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.
Eligibility Criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven NSCLC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy * A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan. Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy * Stage IV
Contact & Investigator
Yu Sun, Ph.D
PRINCIPAL INVESTIGATOR
Shanghai Jiao Tong University School of Medicine
Frequently Asked Questions
Who can join the NCT02889666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Recurrent Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT02889666 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT02889666 currently recruiting?
Yes, NCT02889666 is actively recruiting participants. Contact the research team at sunyu@sibs.ac.cn for enrollment information.
Where is the NCT02889666 trial being conducted?
This trial is being conducted at Changchun, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT02889666 clinical trial?
NCT02889666 is sponsored by Shanghai Jiao Tong University School of Medicine. The principal investigator is Yu Sun, Ph.D at Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.